From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS

In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...
WIB_icon

Early-Phase Trial Shows Venetoclax Plus HMA Has High Response Rates in Older Patients With...

In a phase Ib dose-escalation and dose-expansion study published in Blood, two-thirds of older patients with acute myeloid leukemia (AML) responded to the combination...
WIB_icon

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...

Eculizumab Reduces Hemolysis and Transfusion Dependency in Patients With Cold Agglutin Disease

Treatment with eculizumab, an inhibitor of the terminal complement pathway, reduced hemolysis and transfusion-dependence in patients with cold agglutin disease (CAD). However, it had...

Phlebotomy and Hydroxyurea Are Underused in Patients With Polycythemia Vera

Treatment with phlebotomy or hydroxyurea was associated with lower mortality among older patients with polycythemia vera (PV) who were considered at high thrombotic risk,...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.